288 related articles for article (PubMed ID: 18496127)
1. Genetic aspects of epitestosterone formation and androgen disposition: influence of polymorphisms in CYP17 and UGT2B enzymes.
Schulze JJ; Lorentzon M; Ohlsson C; Lundmark J; Roh HK; Rane A; Ekström L
Pharmacogenet Genomics; 2008 Jun; 18(6):477-85. PubMed ID: 18496127
[TBL] [Abstract][Full Text] [Related]
2. Doping test results dependent on genotype of uridine diphospho-glucuronosyl transferase 2B17, the major enzyme for testosterone glucuronidation.
Schulze JJ; Lundmark J; Garle M; Skilving I; Ekström L; Rane A
J Clin Endocrinol Metab; 2008 Jul; 93(7):2500-6. PubMed ID: 18334593
[TBL] [Abstract][Full Text] [Related]
3. Discordant genotyping results using DNA isolated from anti-doping control urine samples.
Choong E; Schulze JJ; Ericsson M; Rane A; Ekström L
Drug Test Anal; 2017 Jul; 9(7):994-1000. PubMed ID: 27706926
[TBL] [Abstract][Full Text] [Related]
4. The uridine diphosphate glucuronosyltransferase 2B15 D85Y and 2B17 deletion polymorphisms predict the glucuronidation pattern of androgens and fat mass in men.
Swanson C; Mellström D; Lorentzon M; Vandenput L; Jakobsson J; Rane A; Karlsson M; Ljunggren O; Smith U; Eriksson AL; Bélanger A; Labrie F; Ohlsson C
J Clin Endocrinol Metab; 2007 Dec; 92(12):4878-82. PubMed ID: 17698910
[TBL] [Abstract][Full Text] [Related]
5. Epidemiological investigation of the UGT2B17 polymorphism in doping control urine samples and its correlation to T/E ratios.
Anielski P; Simmchen J; Wassill L; Ganghofner D; Thieme D
Drug Test Anal; 2011 Oct; 3(10):645-51. PubMed ID: 21928278
[TBL] [Abstract][Full Text] [Related]
6. Dose-dependent testosterone sensitivity of the steroidal passport and GC-C-IRMS analysis in relation to the UGT2B17 deletion polymorphism.
Strahm E; Mullen JE; Gårevik N; Ericsson M; Schulze JJ; Rane A; Ekström L
Drug Test Anal; 2015; 7(11-12):1063-70. PubMed ID: 26198073
[TBL] [Abstract][Full Text] [Related]
7. Bioavailability of testosterone enanthate dependent on genetic variation in the phosphodiesterase 7B but not on the uridine 5'-diphospho-glucuronosyltransferase (UGT2B17) gene.
Ekström L; Schulze JJ; Guillemette C; Belanger A; Rane A
Pharmacogenet Genomics; 2011 Jun; 21(6):325-32. PubMed ID: 21383644
[TBL] [Abstract][Full Text] [Related]
8. [Testosterone metabolism and doping test results].
Laczmański Ł; Medraś M
Endokrynol Pol; 2009; 60(1):58-62. PubMed ID: 19224506
[TBL] [Abstract][Full Text] [Related]
9. Androgen sulfation in healthy UDP-glucuronosyl transferase 2B17 enzyme-deficient men.
Schulze JJ; Thörngren JO; Garle M; Ekström L; Rane A
J Clin Endocrinol Metab; 2011 Nov; 96(11):3440-7. PubMed ID: 21849521
[TBL] [Abstract][Full Text] [Related]
10. Non-steroidal anti-inflammatory drugs interact with testosterone glucuronidation.
Sten T; Finel M; Ask B; Rane A; Ekström L
Steroids; 2009 Nov; 74(12):971-7. PubMed ID: 19643121
[TBL] [Abstract][Full Text] [Related]
11. UDP-glucuronosyltransferase 2B17 genotyping in Japanese athletes and evaluation of the current sports drug testing for detecting testosterone misuse.
Okano M; Ueda T; Nishitani Y; Kano H; Ikekita A; Kageyama S
Drug Test Anal; 2013 Mar; 5(3):166-81. PubMed ID: 22887913
[TBL] [Abstract][Full Text] [Related]
12. UDP-glucuronosyltransferases (UGTs) 2B7 and UGT2B17 display converse specificity in testosterone and epitestosterone glucuronidation, whereas UGT2A1 conjugates both androgens similarly.
Sten T; Bichlmaier I; Kuuranne T; Leinonen A; Yli-Kauhaluoma J; Finel M
Drug Metab Dispos; 2009 Feb; 37(2):417-23. PubMed ID: 19022937
[TBL] [Abstract][Full Text] [Related]
13. [Introduction of genetic analysis can provide us with safer doping tests. Large variation in androgen turnover creates problems in current tests].
Rane A; Ekström L
Lakartidningen; 2012 Jul 18-Aug 8; 109(29-31):1347-9. PubMed ID: 22913116
[No Abstract] [Full Text] [Related]
14. Testosterone challenge and androgen receptor activity in relation to UGT2B17 genotypes.
Ekström L; Cevenini L; Michelini E; Schulze J; Thörngren JO; Belanger A; Guillemette C; Garle M; Roda A; Rane A
Eur J Clin Invest; 2013 Mar; 43(3):248-55. PubMed ID: 23294483
[TBL] [Abstract][Full Text] [Related]
15. Substantial advantage of a combined Bayesian and genotyping approach in testosterone doping tests.
Schulze JJ; Lundmark J; Garle M; Ekström L; Sottas PE; Rane A
Steroids; 2009 Mar; 74(3):365-8. PubMed ID: 19056415
[TBL] [Abstract][Full Text] [Related]
16. A novel polymorphism in a forkhead box A1 (FOXA1) binding site of the human UDP glucuronosyltransferase 2B17 gene modulates promoter activity and is associated with altered levels of circulating androstane-3α,17β-diol glucuronide.
Hu DG; Gardner-Stephen D; Severi G; Gregory PA; Treloar J; Giles GG; English DR; Hopper JL; Tilley WD; Mackenzie PI
Mol Pharmacol; 2010 Oct; 78(4):714-22. PubMed ID: 20628005
[TBL] [Abstract][Full Text] [Related]
17. Relative enzymatic activity, protein stability, and tissue distribution of human steroid-metabolizing UGT2B subfamily members.
Turgeon D; Carrier JS; Lévesque E; Hum DW; Bélanger A
Endocrinology; 2001 Feb; 142(2):778-87. PubMed ID: 11159850
[TBL] [Abstract][Full Text] [Related]
18. A common deletion in the uridine diphosphate glucuronyltransferase (UGT) 2B17 gene is a strong determinant of androgen excretion in healthy pubertal boys.
Juul A; Sørensen K; Aksglaede L; Garn I; Rajpert-De Meyts E; Hullstein I; Hemmersbach P; Ottesen AM
J Clin Endocrinol Metab; 2009 Mar; 94(3):1005-11. PubMed ID: 19088161
[TBL] [Abstract][Full Text] [Related]
19. Re-evaluation of combined ((ES/EG)/(TS/TG)) ratio as a marker of testosterone intake in men.
Schulze J; Pettersson-Bohlin K; Thörngren JO; Ekström L
Drug Test Anal; 2021 Aug; 13(8):1576-1579. PubMed ID: 33864421
[TBL] [Abstract][Full Text] [Related]
20. Inactivation of androgens by UDP-glucuronosyltransferases in the human prostate.
Barbier O; Bélanger A
Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):259-70. PubMed ID: 18471784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
